{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T12:40:29Z","timestamp":1740573629120,"version":"3.38.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s00393-025-01616-0","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T09:22:23Z","timestamp":1740129743000},"page":"128-137","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Seltene osteologische Erkrankungen in der rheumatologischen Sprechstunde: Hypophosphatasie und Phosphatverlustsyndrome","Rare osteological diseases in the rheumatological consultation: hypophosphatasia and phosphate loss syndromes"],"prefix":"10.1007","volume":"84","author":[{"given":"Claus-J\u00fcrgen","family":"Bauer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentin S.","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhivana","family":"Boyadzhieva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Burkhard","family":"Muche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,21]]},"reference":[{"key":"1616_CR1","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1136\/annrheumdis-2024-eular.3631","volume":"83","author":"C Bauer","year":"2024","unstructured":"Bauer\u00a0C (2024) Prospective study on prevalence and diagnostic algorithms for hypophosphatasia detection in adult rheumatology patients\u2014the COHIR study. Ann Rheum Dis 83:472\u2013473","journal-title":"Ann Rheum Dis"},{"key":"1616_CR2","doi-asserted-by":"publisher","first-page":"116947","DOI":"10.1016\/j.bone.2023.116947","volume":"178","author":"MR Farman","year":"2024","unstructured":"Farman\u00a0MR, Rehder\u00a0C, Malli\u00a0T et\u00a0al (2024) The Global ALPL gene variant classification project: Dedicated to deciphering variants. Bone 178:116947","journal-title":"Bone"},{"key":"1616_CR3","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1007\/s00330-020-07342-2","volume":"31","author":"Q He","year":"2021","unstructured":"He\u00a0Q, Zhang\u00a0B, Zhang\u00a0L et\u00a0al (2021) Diagnostic efficiency of (68)Ga-DOTANOC PET\/CT in patients with suspected tumour-induced osteomalacia. Eur Radiol 31:2414\u20132421","journal-title":"Eur Radiol"},{"key":"1616_CR4","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s00393-021-00994-5","volume":"81","author":"P Karakostas","year":"2022","unstructured":"Karakostas\u00a0P, Dolscheid-Pommerich\u00a0R, Hass\u00a0MD et\u00a0al (2022) Prevalence of hypophosphatasia in adult patients in rheumatology. Z\u00a0Rheumatol 81:513\u2013519","journal-title":"Z Rheumatol"},{"key":"1616_CR5","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s12149-021-01575-x","volume":"35","author":"A Kato","year":"2021","unstructured":"Kato\u00a0A, Nakamoto\u00a0Y, Ishimori\u00a0T et\u00a0al (2021) Diagnostic performance of (68)Ga-DOTATOC PET\/CT in tumor-induced osteomalacia. Ann Nucl Med 35:397\u2013405","journal-title":"Ann Nucl Med"},{"key":"1616_CR6","doi-asserted-by":"publisher","first-page":"e18351","DOI":"10.1097\/MD.0000000000018351","volume":"98","author":"D Lee","year":"2019","unstructured":"Lee\u00a0D, Yun\u00a0BC, Seo\u00a0KI et\u00a0al (2019) Risk factors associated with hypophosphatemia in chronic Hepatitis\u00a0B patients treated with tenofovir disoproxil fumarate. Medicine 98:e18351","journal-title":"Medicine"},{"key":"1616_CR7","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.berh.2007.11.003","volume":"22","author":"E Mornet","year":"2008","unstructured":"Mornet\u00a0E (2008) Hypophosphatasia. Best Pract Res Clin Rheumatol 22:113\u2013127","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"1616_CR8","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ejim.2015.12.019","volume":"29","author":"L Riancho-Zarrabeitia","year":"2016","unstructured":"Riancho-Zarrabeitia\u00a0L, Garcia-Unzueta\u00a0M, Tenorio\u00a0JA et\u00a0al (2016) Clinical, biochemical and genetic spectrum of low alkaline phosphatase levels in adults. Eur J Intern Med 29:40\u201345","journal-title":"Eur J Intern Med"},{"issue":"2","key":"1616_CR9","first-page":"380","volume":"10","author":"C Rockman-Greenberg","year":"2013","unstructured":"Rockman-Greenberg\u00a0C (2013) Hypophosphatasia. Pediatr Endocrinol Rev 10(2):380\u2013388","journal-title":"Pediatr Endocrinol Rev"},{"key":"1616_CR10","doi-asserted-by":"publisher","first-page":"153892","DOI":"10.1016\/j.metabol.2019.03.009","volume":"103S","author":"A Rothenbuhler","year":"2020","unstructured":"Rothenbuhler\u00a0A, Schnabel\u00a0D, Hogler\u00a0W et\u00a0al (2020) Diagnosis, treatment-monitoring and follow-up of children and adolescents with X\u2011linked hypophosphatemia (XLH). Metabolism 103S:153892","journal-title":"Metabolism"},{"key":"1616_CR11","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13023-019-1062-0","volume":"14","author":"SM Szabo","year":"2019","unstructured":"Szabo\u00a0SM, Tomazos\u00a0IC, Petryk\u00a0A et\u00a0al (2019) Frequency and age at occurrence of clinical manifestations of disease in patients with hypophosphatasia: a\u00a0systematic literature review. Orphanet J Rare Dis 14:85","journal-title":"Orphanet J Rare Dis"},{"key":"1616_CR12","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41574-022-00662-x","volume":"18","author":"A Trombetti","year":"2022","unstructured":"Trombetti\u00a0A, Al-Daghri\u00a0N, Brandi\u00a0ML et\u00a0al (2022) Interdisciplinary management of FGF23-related phosphate wasting syndromes: a\u00a0Consensus Statement on the evaluation, diagnosis and care of patients with X\u2011linked hypophosphataemia. Nat Rev Endocrinol 18:366\u2013384","journal-title":"Nat Rev Endocrinol"},{"key":"1616_CR13","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/nrendo.2016.14","volume":"12","author":"MP Whyte","year":"2016","unstructured":"Whyte\u00a0MP (2016) Hypophosphatasia\u2014aetiology, nosology, pathogenesis, diagnosis and treatment. Nat Rev Endocrinol 12:233\u2013246","journal-title":"Nat Rev Endocrinol"},{"key":"1616_CR14","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s00774-004-0589-9","volume":"23","author":"T Yamamoto","year":"2005","unstructured":"Yamamoto\u00a0T, Imanishi\u00a0Y, Kinoshita\u00a0E et\u00a0al (2005) The role of fibroblast growth factor\u00a023 for hypophosphatemia and abnormal regulation of vitamin\u00a0D metabolism in patients with McCune-Albright syndrome. J\u00a0Bone Miner Metab 23:231\u2013237","journal-title":"J Bone Miner Metab"},{"key":"1616_CR15","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1136\/gutjnl-2022-327897","volume":"72","author":"H Zoller","year":"2023","unstructured":"Zoller\u00a0H, Wolf\u00a0M, Blumenstein\u00a0I et\u00a0al (2023) Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a\u00a0randomised clinical trial. Gut 72:644\u2013653","journal-title":"Gut"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-025-01616-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-025-01616-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-025-01616-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T11:43:33Z","timestamp":1740570213000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-025-01616-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,21]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["1616"],"URL":"https:\/\/doi.org\/10.1007\/s00393-025-01616-0","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"type":"print","value":"0340-1855"},{"type":"electronic","value":"1435-1250"}],"subject":[],"published":{"date-parts":[[2025,2,21]]},"assertion":[{"value":"27 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"C.-J.\u00a0Bauer macht folgende Angaben: Vortragshonorare von Lilly, Novartis, Bristol-Myers Squibb, Galapagos, Janssen-Cilag, UCB, AstraZeneca, Abbvie; Beratungshonorar von Abbvie; Forschungsunterst\u00fctzung von Alexion. V.S.\u00a0Sch\u00e4fer macht folgende Angaben: Vortragshonorare von Abbvie, Novartis, BMS, Chugai, Celgene, Medac, Sanofi, Lilly, Hexal, Pfizer, Janssen, Roche, Shire, Onkowissen, Royal College London, Boehringer-Ingelheim, UCB, Fresenius, Alexion; Beratungshonorare von Novartis, Chugai, Abbvie, Celgene, Sanofi, Lilly, Hexal, Pfizer, Amgen, BMS, Roche, Gilead, Medac, Boehringer-Ingelheim, Alexion; Forschungsunterst\u00fctzung von Novartis, Hexal, Lilly, Roche, Celgene, Universit\u00e4t Bonn, Boehringer-Ingelheim, Butterfly IQ, Medac, Alexion, Deutsche Gesellschaft f\u00fcr Rheumatologie, Bundesministerium f\u00fcr Bildung und Forschung. B.\u00a0Muche macht folgende Angaben: Vortragshonorare von Alexion, Amgen, Fachverband Rheumatologische Fachassistenz e.V., OSTAK, Osteologie Akademie GmbH, UCB; Beratungshonorare von Alexion, Amgen, Celltrion, Galapagos, Theramex, UCB. Z.\u00a0Boyadzhieva gibt an, dass kein Intereressenskonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patient\/-innen zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern\/Vertreterinnen eine schriftliche Einwilligung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}